stockrowTarsus Pharmaceuticals, Inc.
TARS Healthcare Biotechnology
Tarsus Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $451.4 million, up 146.7% from fiscal 2024.
- Revenue
- +63.9%
- EPS
- −4,699.1%
- Free cash flow
- −144.1%
- Total debt
- +0.90%
Quarter to September 2026, against a year earlier
Follow TARS
Alert me
Tarsus Pharmaceuticals, Inc. (TARS) EV/Sales
As of 5 November 2026, Tarsus Pharmaceuticals, Inc. (TARS) trades at a EV/Sales of 4.2×. Over the past ten years it has ranged from 0.0× (December 2021) to 34.8× (February 2024); the current reading is higher than 26% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 6.8× | (33.07%) |
| FY2024 | 10.2× | (29.21%) |
| FY2023 | 14.4× | 138.93% |
| FY2022 | 6.0× | 17.86% |
| FY2021 | 5.1× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 5.0× | 28.83% |
| Jun 2026 | 3.9× | (22.97%) |
| Mar 2026 | 5.0× | (26.03%) |
| Dec 2025 | 6.8× | 13.27% |
| 17 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VKTX Viking Therapeutics, Inc. compare | n/m |
| TLX Telix Pharmaceuticals Limited compare | n/m |
| CELC Celcuity, Inc. compare | n/m |
| DYN Dyne Therapeutics, Inc. compare | n/m |
| ELVN Enliven Therapeutics, Inc. compare | n/m |
| ACAD ACADIA Pharmaceuticals Inc. compare | 2.2× |
| TARS Tarsus Pharmaceuticals, Inc. | 4.2× |
| VRDN Viridian Therapeutics, Inc. compare | 91.0× |
| DNLI Denali Therapeutics Inc. compare | 143× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on TARS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement